Specificity in the interaction of natural products with their target proteins- A biochemical and structural insight

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 6, 2010, Pages 540-549

  Venkatraman, P ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Cancer; Mechanism; Molecular target; Natural products; Specificity; Structure

Indexed keywords

APOGOSSYPOL; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; EPIDITHIODIKETOPIPERAZINE; FLAVOPIRIDOL; FUMAGILLIN; GOSSYPOL DERIVATIVE; IMATINIB; NATURAL PRODUCT; PLADIENOLIDE; PROTEASOME INHIBITOR; PROTEIN MDM2; PROTEIN P53; RESVERATROL; SALINOSPORAMIDE A; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG BINDING; DRUG TARGETING; HUMAN; IN VIVO STUDY; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NONHUMAN; PLASMACYTOMA; PROTEIN PROTEIN INTERACTION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CYCLOHEXANES; EPOXY COMPOUNDS; FATTY ACIDS, UNSATURATED; FLAVONOIDS; HUMANS; MACROLIDES; NEOPLASMS; PIPERAZINES; PIPERIDINES; PROTEINS; PYRIMIDINES; SESQUITERPENES;

EID: 77953709832     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710791384090     Document Type: Article

References (90)

1. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70, 461-77.
2. Hung, D. T.; Jamison, T. F.; Schreiber, S. L. Understanding and controlling the cell cycle with natural products. Chem. Biol., 1996, 3, 623-39.
3. Patel, R.; Krishnan, R.; Ramchandani, A.; Maru, G. Polymeric black tea polyphenols inhibit mouse skin chemical carcinogenesis by decreasing cell proliferation. Cell Prolif., 2008, 41, 532-53.
4. Jagtap, S.; Meganathan, K.; Wagh, V.; Winkler, J.; Hescheler, J.; Sachinidis, A. Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr. Med. Chem., 2009, 16, 1451-62.
5. Shi, Y.; Sahu, R. P.; Srivastava, S. K. Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosis. BMC Cancer, 2008, 8, 294.
6. Bar-Sela, G.; Epelbaum, R.; Schaffer, M. Curcumin as an anticancer agent: review of the gap between basic and clinical applications. Curr. Med. Chem., 2010, 17(3), 190-197.
7. Ravindran, J.; Prasad, S.; Aggarwal, B. B. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS. J., 2009, 11, 495-510.
8. da Rocha, A. B.; Lopes, R. M.; Schwartsmann, G. Natural products in anticancer therapy. Curr. Opin. Pharmacol., 2001, 1, 364-9.
9. Colic, M.; Pavelic, K. Molecular mechanisms of anticancer activity of natural dietetic products. J. Mol. Med., 2000, 78, 333-336.
10. Sarkar, F. H.; Li, Y. Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat. Rev., 2009, 35, 597-607.
11. Staker, B. L.; Hjerrild, K.; Feese, M. D.; Behnke, C. A.; Burgin, A. B. Jr.; Stewart, L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. USA, 2002, 99, 15387-15392.
12. Kik, K.; Wasowska-Lukawska, M.; Oszczapowicz, I.; Szmigiero, L. Cytotoxicity and cellular uptake of doxorubicin and its formamidine derivatives in HL60 sensitive and HL60/MX2 resistant cells. Anticancer Res., 2009, 29, 1429-1433.
13. Dal Ben, D.; Palumbo, M.; Zagotto, G.; Capranico, G.; Moro, S. DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation. Curr. Pharm. Des., 2007, 13, 2766-2780.
14. Druker, B. J. Imatinib as a paradigm of targeted therapies. Adv. Cancer Res., 2004, 91, 1-30.
15. Sanford, M.; Scott, L. J. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. Drugs, 2009, 69, 2303-2328.
16. Kingston, D. G. Tubulin-interactive natural products as anticancer agents (1). J. Nat. Prod., 2009, 72, 507-515.
17. Saklani, A.; Kutty, S. K. Plant-derived compounds in clinical trials. Drug Discov. Today, 2008, 13, 161-171.
18. Dancey, J. E.; Chen, H. X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov., 2006, 5, 649-659.
19. Kitada, S.; Kress, C. L.; Krajewska, M.; Jia, L.; Pellecchia, M.; Reed, J. C. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood, 2008, 111, 3211-3219.
20. Quesada, A. R.; Munoz-Chapuli, R.; Medina, M. A. Antiangiogenic drugs: from bench to clinical trials. Med. Res. Rev., 2006, 26, 483-530.
21. Murray, J. K.; Gellman, S. H. Targeting protein-protein interactions: lessons from p53/MDM2. Biopolymers, 2007, 88, 657-686.
22. Adams, J.; Kauffman, M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest., 2004, 22, 304-311.
23. Fukuyo, Y.; Hunt, C. R.; Horikoshi, N. Geldanamycin and its anticancer activities. Cancer Lett., 2010, 290, 24-35.
24. Bailly, C. Ready for a comeback of natural products in oncology. Biochem. Pharmacol., 2009, 77, 1447-1457.
25. Lesko, E.; Gozdzik, J.; Kijowski, J.; Jenner, B.; Wiecha, O.; Majka, M. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo. Anticancer Drugs, 2007, 18, 1173-1181.
26. Sugimoto, K.; Sasaki, M.; Isobe, Y.; Tsutsui, M.; Suto, H.; Ando, J.; Tamayose, K.; Ando, M.; Oshimi, K. Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1. Oncogene, 2008, 27, 3091-3101.
27. Tsan, M. F.; White, J. E.; Maheshwari, J. G.; Chikkappa, G. Antileukemia effect of resveratrol. Leuk. Lymphoma, 2002, 43, 983-987.
28. Nikrad, M.; Johnson, T.; Puthalalath, H.; Coultas, L.; Adams, J.; Kraft, A. S. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol. Cancer Ther., 2005, 4, 443-449.
29. Nawrocki, S. T.; Bruns, C. J.; Harbison, M. T.; Bold, R. J.; Gotsch, B. S.; Abbruzzese, J. L.; Elliott, P.; Adams, J.; McConkey, D. J. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol. Cancer Ther., 2002, 1, 1243-1253.
30. Goldberg, A. L. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem. Soc. Trans., 2007, 35, 12-17.
31. Kamb, A.; Wee, S.; Lengauer, C. Why is cancer drug discovery so difficult? Nat. Rev. Drug Discov., 2007, 6, 115-120.
32. Seeliger, M. A.; Ranjitkar, P.; Kasap, C.; Shan, Y.; Shaw, D. E.; Shah, N. P.; Kuriyan, J.; Maly, D. J. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res., 2009, 69, 2384-2392.
33. Seeliger, M. A.; Nagar, B.; Frank, F.; Cao, X.; Henderson, M. N.; Kuriyan, J. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure, 2007, 15, 299-311.
34. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 2005, 7, 129-141.
35. Winger, J. A.; Hantschel, O.; Superti-Furga, G.; Kuriyan, J. The structure of the leukemia drug imatinib bound to human quinine reductase 2 (NQO2). BMC Struct. Biol., 2009, 9, 7.
36. Vella, F.; Ferry, G.; Delagrange, P.; Boutin, J. A. NRH:quinine reductase 2: an enzyme of surprises and mysteries. Biochem. Pharmacol., 2005, 71, 1-12.
37. Buryanovskyy, L.; Fu, Y.; Boyd, M.; Ma, Y.; Hsieh, T. C.; Wu, J. M.; Zhang, Z. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry, 2004, 43, 11417-11426.
38. Fontecave, M.; Lepoivre, M.; Elleingand, E.; Gerez, C.; Guittet, O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett., 1998, 421, 277-279.
39. Wang, Z.; Hsieh, T. C.; Zhang, Z.; Ma, Y.; Wu, J. M. Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem. Biophys. Res. Commun., 2004, 323, 743-749.
40. Kipp, J. L.; Ramirez, V. D. Effect of estradiol, diethylstilbestrol, and resveratrol on F0F1-ATPase activity from mitochondrial preparations of rat heart, liver, and brain. Endocrine, 2001, 15, 165-175.
41. Liang, Y. C.; Tsai, S. H.; Chen, L.; Lin-Shiau, S. Y.; Lin, J. K. Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem. Pharmacol., 2003, 65, 1053-1060.
42. Shao, J.; Zhou, B.; Chu, B.; Yen, Y. Ribonucleotide reductase inhibitors and future drug design. Curr. Cancer Drug Targets, 2006, 6, 409-4031.
43. Cerqueira, N. M.; Pereira, S.; Fernandes, P. A.; Ramos, M. J. Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy. Curr. Med. Chem., 2005, 12, 1283-1294.
44. Rix, U.; Hantschel, O.; Durnberger, G.; Remsing Rix, L. L.; Planyavsky, M.; Fernbach, N. V.; Kaupe, I.; Bennett, K. L.; Valent, P.; Colinge, J.; Kocher, T.; Superti-Furga, G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood, 2007, 110, 4055-4063.
45. Larsson, K. M.; Andersson, J.; Sjoberg, B. M.; Nordlund, P.; Logan, D. T. Structural basis for allosteric substrate specificity regulation in anaerobic ribonucleotide reductases. Structure, 2001, 9, 739-750.
46. Larsson, K. M.; Jordan, A.; Eliasson, R.; Reichard, P.; Logan, D. T.; Nordlund, P. Structural mechanism of allosteric substrate specificity regulation in a ribonucleotide reductase. Nat. Struct. Mol. Biol., 2004, 11, 1142-1149.
47. Goodsell, D. S.; Morris, G. M.; Olson, A. J. Automated docking of flexible ligands: applications of AutoDock. J. Mol. Recognit., 1996, 9, 1-5.
48. Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol., 2006, 24, 1770-1783.
49. Baumli, S.; Lolli, G.; Lowe, E. D.; Troiani, S.; Rusconi, L.; Bullock, A. N.; Debreczeni, J. E.; Knapp, S.; Johnson, L. N. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J., 2008, 27, 1907-1918.
50. Sambol, E. B.; Ambrosini, G.; Geha, R. C.; Kennealey, P. T.; Decarolis, P.; O'Connor, R.; Wu, Y. V.; Motwani, M.; Chen, J. H.; Schwartz, G. K.; Singer, S. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res., 2006, 66, 5858-5866.
51. Oikonomakos, N. G.; Schnier, J. B.; Zographos, S. E.; Skamnaki, V. T.; Tsitsanou, K. E.; Johnson, L. N. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site. J. Biol. Chem. 2000, 275, 34566-34573.
52. Kaiser, A.; Nishi, K.; Gorin, F. A.; Walsh, D. A.; Bradbury, E. M.; Schnier, J. B. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase. Arch. Biochem. Biophys., 2001, 386, 179-187.
53. De Azevedo, W. F. Jr.; Mueller-Dieckmann, H. J.; Schulze-Gahmen, U.; Worland, P. J.; Sausville, E.; Kim, S. H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA, 1996, 93, 2735-2740.
54. Pellecchia, M.; Reed, J. C. Inhibition of anti-apoptotic Bcl-2 family proteins by natural polyphenols: new avenues for cancer chemoprevention and chemotherapy. Curr. Pharm. Des., 2004, 10, 1387-1398.
55. Yang, G. Y.; Liao, J.; Kim, K.; Yurkow, E. J.; Yang, C. S. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis, 1998, 19, 611-616.
56. Leone, M.; Zhai, D.; Sareth, S.; Kitada, S.; Reed, J. C.; Pellecchia, M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res., 2003, 63, 8118-8121.
57. O'Brien, S.; Moore, J. O.; Boyd, T. E.; Larratt, L. M.; Skotnicki, A.; Koziner, B.; Chanan-Khan, A. A.; Seymour, J. F.; Bociek, R. G.; Pavletic, S.; Rai, K. R. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2007, 25, 1114-1120.
58. Flinn, I. W.; Neuberg, D. S.; Grever, M. R.; Dewald, G. W.; Bennett, J. M.; Paietta, E. M.; Hussein, M. A.; Appelbaum, F. R.; Larson, R. A.; Moore, D. F. Jr.; Tallman, M. S. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol., 2007, 25, 793-798.
59. Banerjee, S.; Choi, M.; Aboukameel, A.; Wang, Z.; Mohammad, M.; Chen, J.; Yang, D.; Sarkar, F. H.; Mohammad, R. M. Preclinical Studies of Apogossypolone, a Novel Pan Inhibitor of Bcl-2 and Mcl-1, Synergistically Potentiates Cytotoxic Effect of Gemcitabine in Pancreatic Cancer Cells. Pancreas., 2010, 39, 323-331.
60. Tachibana, H.; Koga, K.; Fujimura, Y.; Yamada, K. A receptor for green tea polyphenol EGCG. Nat. Struct. Mol. Biol., 2004, 11, 380-381.
61. Nam, S.; Smith, D. M.; Dou, Q. P. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem., 2001, 276, 13322-13330.
62. Tachibana, H. Molecular basis for cancer chemoprevention by green tea polyphenol EGCG. Forum Nutr., 2009, 61, 156-169.
63. Cook, K. M.; Hilton, S. T.; Mecinovic, J.; Motherwell, W. B.; Figg, W. D.; Schofield, C. J. Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J. Biol. Chem., 2009, 284, 26831-26838.
64. Pickart, C. M. Back to the future with ubiquitin. Cell, 2004, 116, 181-190.
65. Ciechanover, A. Intracellular protein degradation from a vague idea through the lysosome and the ubiquitin-proteasome system and on to human diseases and drug targeting: Nobel Lecture, December 8, 2004. Ann. N. Y. Acad. Sci., 2007, 1116, 1-28.
66. Wilkinson, K. D. Ubiquitin: a Nobel protein. Cell, 2004, 119, 741-745.
67. Glickman, M. H.; Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev., 2002, 82, 373-428.
68. Nalepa, G.; Rolfe, M.; Harper, J. W. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 2006, 5, 596-613.
69. Popowicz, G. M.; Czarna, A.; Rothweiler, U.; Szwagierczak, A.; Krajewski, M.; Weber, L.; Holak, T. A. Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle, 2007, 6, 2386-2392.
70. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 2004, 303, 844-848.
71. Burgoyne, N. J.; Jackson, R. M. Predicting protein interaction sites: binding hot-spots in protein-protein and protein-ligand interfaces. Bioinformatics, 2006, 22, 1335-1342.
72. Fuertes, G.; Martin De Llano, J. J.; Villarroya, A.; Rivett, A. J.; Knecht, E. Changes in the proteolytic activities of proteasomes and lysosomes in human fibroblasts produced by serum withdrawal, amino-acid deprivation and confluent conditions. Biochem. J., 2003, 375, 75-86.
73. Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N.; Yasui, H.; Letai, A.; Ovaa, H.; Berkers, C.; Nicholson, B.; Chao, T. H.; Neuteboom, S. T.; Richardson, P.; Palladino, M. A.; Anderson, K. C. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell, 2005, 8, 407-419.
74. Groll, M.; Nazif, T.; Huber, R.; Bogyo, M. Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome. Chem. Biol., 2002, 9, 655-662.
75. Navon, A.; Ciechanover, A. The 26 S proteasome: from basic mechanisms to drug targeting. J. Biol. Chem., 2009, 284, 33713-33718.
76. Chauhan, D.; Singh, A.; Brahmandam, M.; Podar, K.; Hideshima, T.; Richardson, P.; Munshi, N.; Palladino, M. A.; Anderson, K. C. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood, 2008, 111, 1654-1664.
77. Kisselev, A. F.; Callard, A.; Goldberg, A. L. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J. Biol. Chem., 2006, 281, 8582-8590.
78. Datta, B. Roles of P67/MetAP2 as a tumor suppressor. Biochim. Biophys. Acta. 2009, 1796, 281-2892.
79. Griffith, E. C.; Su, Z.; Niwayama, S.; Ramsay, C. A.; Chang, Y. H.; Liu, J. O. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc. Natl. Acad. Sci. USA, 1998, 95, 15183-15188.
80. Brdlik, C. M.; Crews, C. M. A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidases. J. Biol. Chem., 2004, 279, 9475-9480.
81. Chen, G.; Heim, A.; Riether, D.; Yee, D.; Milgrom, Y.; Gawinowicz, M. A.; Sames, D. Reactivity of functional groups on the protein surface: development of epoxide probes for protein labeling. J. Am. Chem. Soc., 2003, 125, 8130-8133.
82. Mizui, Y.; Sakai, T.; Iwata, M.; Uenaka, T.; Okamoto, K.; Shimizu, H.; Yamori, T.; Yoshimatsu, K.; Asada, M. Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities. J Antibiot. (Tokyo), 2004, 57, 188-196.
83. Kotake, Y.; Sagane, K.; Owa, T.; Mimori-Kiyosue, Y.; Shimizu, H.; Uesugi, M.; Ishihama, Y.; Iwata, M.; Mizui, Y. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat. Chem. Biol., 2007, 3, 570-575.
84. Cheng, K. W.; Wong, C. C.; Wang, M.; He, Q. Y.; Chen, F. Identification and characterization of molecular targets of natural products by mass spectrometry. Mass Spectrom. Rev., 29, 126-155.
85. Keiser, M. J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; Jensen, N. H.; Kuijer, M. B.; Matos, R. C.; Tran, T. B.; Whaley, R.; Glennon, R. A.; Hert, J.; Thomas, K. L.; Edwards, D. D.; Shoichet, B. K.; Roth, B. L. Predicting new molecular targets for known drugs. Nature, 2009, 462, 175-181.
86. Chen, X.; Ung, C. Y.; Chen, Y. Can an in silico drug-target search method be used to probe potential mechanisms of medicinal plant ingredients? Nat. Prod. Rep., 2003, 20, 432-444.
87. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov., 2002, 1, 493-502.
88. Byrd, J. C.; Lin, T. S.; Dalton, J. T.; Wu, D.; Phelps, M. A.; Fischer, B.; Moran, M.; Blum, K. A.; Rovin, B.; Brooker- McEldowney, M.; Broering, S.; Schaaf, L. J.; Johnson, A. J.; Lucas, D. M.; Heerema, N. A.; Lozanski, G.; Young, D. C.; Suarez, J. R.; Colevas, A. D.; Grever, M. R. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 2007, 109, 399-404.
89. Drahl, C.; Cravatt, B. F.; Sorensen, E. J. Protein-reactive natural products. Angew Chem. Int. Ed. Engl., 2005, 44, 5788-5809.
90. Bernier, S. G.; Taghizadeh, N.; Thompson, C. D.; Westlin, W. F.; Hannig, G. Methionine aminopeptidases type I and type II are essential to control cell proliferation. J Cell Biochem., 2005, 95, 1191-1203.